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carbapenemase production for routine laboa b s t r a c t
Bacteroides fragilis is a frequent anaerobic pathogen and can cause severe infections. Resistance to car-
bapenems, associated with the cfiA gene encoded carbapenemase, represents an emerging problem. To
date, no rapid methods are available to detect and confirm this resistance mechanism in routine labo-
ratories, and the missed recognition of carbapenemase-producing strains can lead to therapeutic failures.
In this study we have investigated a whole MALDI-TOF MS-based workflow to detect carbapenemase-
producing B. fragilis, using the largest set of B. fragilis clinical isolates ever tested. The presence of the
cfiA gene was predicted by MALDI subtyping into Division I (cfiA-negative) or Division II (cfiA-positive).
The carbapenemase activity in cfiA-positive strains was confirmed by a MALDI-TOF MS imipenem hy-
drolysis assay (MBT STAR-Carba, Bruker Daltonik, Germany), that was further used for a characterization
of the strains in terms of cfiA expression level.
The validity of MALDI subtyping was verified by PCR for the cfiA gene, while results of MALDI hy-
drolysis assay were compared to conventional methods for susceptibility testing and carbapenemase
detection (Carba-NP and disk diffusion synergy test). A genetic analysis of the IS elements upstream cfiA
was performed, for the evaluations regarding the expression level of cfiA. A total of 5300 B. fragilis iso-
lates (406 from Bologna, Italy, and 4894 from Dortmund, Germany) were identified and subtyped by
MALDI-TOF MS, yielding 41/406 (10.1%) strains from Bologna and 374/4894 (7.6%) from Dortmund to
belong to Division II. Molecular verification by PCR for the cfiA gene on a subset of strains confirmed the
MALDI typing results in all cases (sensitivity and specificity of 100%). MBT STAR-Carba assay detected the
carbapenemase activity in all of the 70 cfiA-carrying strains tested. Moreover, it allowed distinct sepa-
ration into slow (59) and fast (11) imipenem hydrolyzers corresponding to cfiA expression levels as well
as to low or high MICs for carbapenems, respectively. Among the 11 cfiA-positive strains with high
carbapenem MIC, only 7 harboured IS elements upstream the carbapenemase gene showing low
expression level as well.
The MALDI-TOF MS-based workflow was superior to the currently available phenotypic methods for
carbapenemase detection as it proved to be more sensitive and accurate than Carba NP and disk diffusion
synergy test. The whole MALDI-TOF MS-based workflow allows an accurate identification of B. fragilis
clinical strains with reliable classification into Division I/II, and confirmation of the carbapenemase-
production, together with estimation of carbapenemase activity, within less than 2 h. This may be of
particular interest for early therapeutical decisions in life-threatening infections.
© 2018 Elsevier Ltd. All rights reserved.Bologna, Italy.
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Bacteroides fragilis is an opportunistic pathogen and may causewholeMALDI-basedworkflow from identification to confirmation of
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counting for only 0.5% of the human colonic flora, B. fragilis is the
most important Gram-negative anaerobic pathogen implicated in
almost every type of infection [1,2]. Furthermore B. fragilis strains
are the most antibiotic resistant organisms among anaerobes [3],
and their resistance rates have increased in the past two decades
[4e6], with a growing number of multidrug resistant (MDR) iso-
lates reported [7e9]. Carbapenems are one of the most effective
treatment options for monobacterial or mixed infections involving
B. fragilis, but carbapenem resistance is an emerging problem
among these strains. A steady trend toward higher MICs of carba-
penems has been observed among B. fragilis strains since the 2000s,
presumably due to increased antibiotic pressure [10e12].
Resistance to carbapenems in B. fragilis is mediated by the cfiA
gene (also known as ccrA), located on the chromosome (even if
exceptions were described) [13], and restricted to Division II of the
species [14]. CfiA encodes a very powerful periplasmatic Ambler
class B di-zinc metallo-beta-lactamase, so far, the unique carba-
penemase enzyme found in B. fragilis, that confers resistance to all
beta-lactam agents, including beta-lactam/beta-lactamase inhibi-
tor combinations [15,16]. CfiA can be either silent or expressed at
different levels, resulting in a broad spectrum of MIC values of
carbapenems, ranging from susceptible to resistant phenotype [17].
The expression level was shown to be mainly related to the pres-
ence of a variety of IS elements carrying outward-oriented pro-
moters, that enhance the carbapenemase expressionwhen inserted
upstream of the cfiA sequence [18], although resistant strains
without such IS elements have also been identified [14,19]. The
spread of cfiA is underestimated, because only strains with the
activated genes and high MIC values can be detected by routine
susceptibility testing, or surveillances. Nevertheless, under selec-
tive pressure during therapy, cfiA positive strains with low MIC
values can undergo a genetic re-arrangement, that results in the
expression of full resistance to carbapenems, leading to therapeutic
failure [20,21].
Routine practice for identification and determination of anti-
microbial susceptibility in anaerobes varies between countries and
laboratories. Most laboratories usually reserve such analyses for
cases where an anaerobic isolate is the predominant pathogen,
since traditional methods for identification and susceptibility
testing are time-consuming, require expertise, and present prob-
lems of interpretation, reproducibility and standardization
[22e24]. To date, no routine tools are available to detect cfiA-har-
bouring strains and to confirm their carbapenemase production.
Conventional methods to detect carbapenem-resistance are not
intended for use with anaerobes, moreover they are slow
(24e48 h), and may lack sensitivity for detection of low-level
resistance [25,26]. Genotypic methods, such as PCR or WGS are
not suitable for routine application [27].
The introduction of matrix assisted laser desorption ionization
time-of-flight mass spectrometry (MALDI-TOF MS) greatly
improved routine identification at species level of anaerobes,
providing a quality of results comparable with molecular methods
[28e30]. Moreover, recently, it has also been proven that MALDI-
TOF MS method is able to differentiate Division I and II of B. fragilis
directly through characteristics in mass spectra, thereby cfiA-
harboring strains can be detected during the identification pro-
cess, directly [31,32]. Furthermore, the possibility to verify the
carbapenemase activity by detecting the cleavage of the antibiotic
molecule after the incubation with the bacterial strain tested has
been described [33,34]. However, the possibility to characterize
the cfiA-harbouring strains in terms of expression level of the
enzyme byMALDI-TOF MS application has not been demonstrated
yet.
The aim of this study was to investigate the applicability inPlease cite this article in press as: M. Cordovana, et al., Bacteroides fragilis: A
carbapenemase production for routine laboratories, Anaerobe (2018), httroutine of a whole MALDI-TOF MS-based diagnostic approach for
the detection of carbapenem-resistance in B. fragilis, analyzing two
large collections of clinical isolates from an Italian and a German
laboratory. The workflow comprises the identification of B. fragilis
strains, the differentiation of the isolates in Division I and II, and the
confirmation of the carbapenemase activity by an imipenem hy-
drolysis assay by MALDI-TOF MS. Furthermore, we compared the
applicability of classical phenotypic methods and the MS-based
method for detection of the carbapenemase activity in case of a
specially selected group of cfiA-positive B. fragilis strains.
2. Materials and methods
2.1. Strains included to the study
Altogether, 5300 non-duplicated B. fragilis strains were iso-
lated in two routine clinical microbiology laboratories. From
March 2013 to May 2017406 B. fragilis strains were isolated in the
Microbiology Unit of the University Hospital (Bologna, Italy) and
4894 strains were isolated from November 2009 to May 2017 in
the Department of Medical Microbiology of the MVZ Dr. Eberhard
& Partner (Dortmund, Germany). The strains were cultured on
Tryptose Soy Agar with 5% sheep blood (Meus, Piove di Sacco,
Italy) in Bologna, and on Schaedler Agar with 5% sheep blood (BD,
Heidelberg, Germany) in Dortmund, for 24e72 h at 35 C, in
anaerobic environment, achieved with AnaeroGen jars (Oxoid,
Basingstoke, UK) or Anoxomat jar system (MART Microbiology,
Drachten, The Netherlands). Identification of the isolates at spe-
cies level was performed in the collecting laboratories, using the
MALDI Biotyper 3.1 system (Bruker Daltonik, Germany), according
to the manufacturer's instructions. High confidence species
identification was accepted, if the log(score) was 2.00, low
confidence species identification log(score) values (1.70
and < 2.00) were accepted if the three best matches showed the
same species name. Any results with log(score) < 1.70 were
considered as an unacceptable identification. Strains were kept
at 80 C for further testing.
Beyond susceptibility testing performed during routine practice
in the collecting laboratories, a selection of n¼ 143 strains was
chosen for further investigations. This subset of isolates included all
the Division II strains isolated from 2014 onwards (n¼ 70, 29 from
Bologna, 41 from Dortmund), and a similar number of Division I
strains, randomly chosen as negative controls (n¼ 73). All these
strains underwent susceptibility testing for carbapenems in
Bologna using standardized conditions. Etest methodology (M.I.C.
Evaluator, Oxoid, UK) was applied according to the EUCAST guide-
lines, version 6.0 (http://www.eucast.org/ast_of_bacteria/
previous_versions_of_documents/). Meropenem MICs were
measured for all these selected strains, while imipenem MICs were
determined for those, which were proven to belong to Division II
and harboured the cfiA gene.
Typing of B. fragilis strains by MALDI-TOF MS, confirmation of
the presence of the cfiA gene by PCR and investigation of the IS
elements.
All the B. fragilis strains with accepted identification on species
level were further investigated to differentiate those belonging to
Division II by the MALDI Biotyper system at the collection sites as
described earlier [31]. The routine identification spectra were
further analyzed by means of MALDI Biotyper 3.1 software by
matching against the previously published cfiA-positive (Division II
B. fragilis) and cfiA-negative (Division I B. fragilis) MSP library. The
above mentioned subgroup of n¼ 143 selected strains (all the
n¼ 70 strains which belonged to Division II by MALDI-TOF MS
isolated from 2014 onwards, and n¼ 73 strains categorized as Di-
vision I byMALDI-TOFMS analysis) underwent confirmation for thewholeMALDI-basedworkflow from identification to confirmation of
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M. Cordovana et al. / Anaerobe xxx (2018) 1e8 3presence of the cfiA gene by PCR. PCR analysis was performed on a
PTC-200 thermal cycler (MJ Research, St. Bruno, Canada) using
0.5 mM of the primers cfiA1 and cfiA2 described in Soki et al. [35]
and 12.5 ml of a 2 ABsoluteBlue QPCR Mix (ThermoFisher Scien-
tific, Waltham, USA). Reaction volume was adjusted to 25 ml with
PCR grade water. The cycling parameters were as follows: 95 C
15min; 94 C 30 s, 62 C 30 s, 72 C 60 s, 30; 72 C for 5min.
The integration of IS elements into upstream regions of the cfiA
genes was determined by end-point PCR for all cfiA-positive strains
as described earlier [35].2.2. Detection of carbapenemase production and activity of the
enzyme by MBT STAR-Carba method
The selection of n¼ 143 B. fragilis strains chosen for deeper
investigations, both cfiA-positive and cfiA-negative isolates, was
investigated by MBT STAR-Carba kit (Bruker Daltonik, Bremen,
Germany) to verify the carbapenemase activity. Application of
this kit for anaerobes is off-label. The assay was performed ac-
cording to manufacturer's instructions for aerobic bacteria with
slight modifications. In brief, a 1 ml loop of bacteria was sus-
pended in 50 ml imipenem solution included in the kit. The sus-
pensions were incubated at 35 C on a shaker for 30min,
centrifuged for 2min, and 1 ml of the supernatant was spotted in
duplicate directly onto a polished steel MALDI target plate. The
pellet was immediately resuspended again, incubated for further
30min, centrifuged for 2min, and a second spotting step was
performed from the supernatant, in order to record, for each
sample, the imipenem mass spectra after 30 and 60min incu-
bation time. The spots were air-dried, overlaid with MBT STAR-
Carba matrix solution. Once dried, the MALDI target plate was
introduced into the Microflex LT mass spectrometer for auto-
matic measurement.
For each run, a positive control (PCR-confirmed KPC-producing
E. coli) and two negative controls (E. coli ATCC 25922 and
B. fragilis ATCC 25285) were also tested. Measurements of mass
spectra were performed using the MBT Compass STAR-BL method
for spectra acquisition. The parameter settings were: ion source 1
19.00 kV, ion source 2 17.05 kV, lens 6.0 kV, detector gain 2.5 kV,
laser frequency 60 Hz. Spectra were recorded in the mass range of
100e1000 Da. For each spot, two spectra were acquired, and each
spectrum was obtained from the sum of 240 laser shots. For cali-
bration, the antibiotic calibration standard (ACS e Bruker Daltonik)
was used according to instructions of the manufacturer. The anal-
ysis of imipenem spectra was performed using a software proto-
type with the identical parameters used in the actual Bruker MBT
STAR-Carba software module. It automatically calculates the loga-
rithmic ratio of the intensity of the internal standard and the in-
tensity of the non-hydrolyzed imipenem molecules, and the logRQ
values of the samples and the controls (logRQ¼ log[internal stan-
dard peak intensity]/[sum non-hydrolyzed peak intensities]). The
logRQ values of the samples are normalized against the logRQ
values of the negative and positive controls, and displayed as
normplots. LogRQ values 0.00 and 1.00 correspond to 0% and 100%
of hydrolytic activity, respectively. LogRQ values 0.2 indicate an
absence of hydrolyzing activity, logRQ values 0.4 indicate the
presence of a carbapenemase activity. LogRQ values between 0.2
and 0.4 means an ambiguous degree of hydrolysis, that requires a
re-testing. For each strain, the comparison between the logRQ re-
sults at 30min and at 60min was performed, to investigate
whether a correlation between the rate of hydrolysis and the car-
bapenem MIC values could be demonstrated, and thereby a char-
acterization of the strains in terms of expression level of cfiA was
possible.Please cite this article in press as:M. Cordovana, et al., Bacteroides fragilis: A
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(Carba NP and disc-diffusion synergy test)
A subset of 29 B. fragilis strains belonging to Division II were
further tested off-label with the available routine methods used to
detect carbapenemase production in Enterobacteriaceae. Namely
the Carba NP test (Neo-Rapid CARB-Kit, Rosco Diagnostics,
Taastrup, Denmark) and the disk diffusion synergy test (KPC/MBL
Confirm Kit e Rosco Diagnostica, Taastrup, Denmark) were evalu-
ated whether they could be a reliable option to detect also the cfiA-
related carbapenemase activity in a group of B. fragilis strains with
different MICs for meropenem (1-32mg/L). Both tests were per-
formed following the manufacturer's instructions. To perform
synergy test, themodifications required for the growth of anaerobic
bacteria were applied (Brucella blood agar (Meus, Piove di Sacco,
Italy) and incubation in anaerobic atmosphere).
3. Results
3.1. Identification of B. fragilis isolates and determination of the
number of isolates belonging to division II in the two centres
In Bologna, 406 B. fragilis clinical isolates were identified by
MALDI-TOFMS at species level during the test period. Overall ID log
score values were between 1.817 and 2.615 (average¼ 2.398, me-
dian¼ 2.435, SD¼ 0.124). During a longer testing period in Dort-
mund 4894 B. fragilis isolates were identified by MALDI-TOF MS at
species level, with overall ID log score values between 1.740 and
2.700 (average¼ 2.411, median¼ 2.430, SD¼ 0.110). The number of
B. fragilis strains belonging to Division II were 41 of 406 (10.1%) in
Bologna and 374 of 4894 (7.6%) in Dortmund. Altogether 415 of
5300 B. fragilis (7.8%) recent clinical isolates were found by the
MALDI-TOFMS typingmethod to belong to Division II, suspicious to
harbour the cfiA gene in an active or inactive form. When we
evaluated the prevalence of Division II isolates in relation to the
source of the specimens, we could observe a significant difference
between Bologna and Dortmund regarding blood cultures. First, we
found that in Bologna, 17 of the 41 (41.5%) B. fragilis strains, which
belonged to Division II, had been isolated from blood cultures,
while in Dortmund only 7 of 374 (1.9%) Division II B. fragilis isolates
were obtained from blood cultures. Second, we found that in
Bologna, the prevalence of Division II strains resulted higher among
isolates from blood cultures (15.2%), in comparison with strains
isolated from all other specimens (8.1%), whereas it was 6% and
7.7%, respectively, in Dortmund.
3.2. Investigation of a subset of B. fragilis isolates belonging to
division I and II for the presence of cfiA gene and the IS elements
In all 70 B. fragilis isolates, belonging in Division II according to
the MALDI-TOF MS typing results (29 from Bologna and 41 from
Dortmund), available for further studies, PCR confirmed the pres-
ence of the cfiA gene. In the case of the other 73 selected B. fragilis
strain which belonged to Division I, none of them gave a positive
PCR result for the cfiA gene (Table 1). Out of the 70 B. fragilis strains
with positive PCR results for the cfiA gene only 7 harboured IS el-
ements upstream of the carbapenemase gene. All strains had a
meropenem MIC 16mg/L. A great variety of the IS elements was
found among these strains, such as IS613 (in two isolates), IS614B
(in two isolates), IS942, IS1169, and IS1187 (each in one isolate)
(Table 1). No IS elements were detected upstream of the cfiA gene in
the strains with lower meropenem MICs (<16mg/L).
MICs of meropenem and imipenem for a subset of B. fragilis
isolates belonging to Division I and II.
The B. fragilis strains belonging to Division I, being cfiA-negativewholeMALDI-basedworkflow from identification to confirmation of
ps://doi.org/10.1016/j.anaerobe.2018.04.004
Table 1
Presence of cfiA and IS elements among a subset of B. fragilis strains belonging to
Division I and II.
B. fragilis (No of isolates) Number of strains positive for
cfiA IS elements
Division I (73)
Bologna (30) 0 nta
Dortmund (43) 0 nta
Division II (70)
Bologna (29) 29 3
MIC MERb 16 5 3 (IS942, IS613, IS614B)
MIC MER <16 24 0
Dortmund (41) 41 4
MIC MER 16 6 4 (IS613, IS614B, IS1169, IS1187)
MIC MER <16 35 0
a Nt: not tested.
b MER meropenem.
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and 2mg/L with slight differences according to the two isolation
centres, confirming full susceptibility of the isolates to carbape-
nems. The cfiA-positive strains all proven to belong to Division II by
the MALDI-TOF MS-based typing, showed meropenem MIC values
between 0.12 and 32mg/L, and the imipenem MIC values were
between 0.06mg/L and 32mg/L. Differences in the distributions
of MIC values both for meropenem and imipenem of cfiA-positive
strains isolated in Bologna and Dortmund were observed, demon-
strating a higher level of resistance in B. fragilis strains isolates in
Bologna (Table 2).3.3. Detection of carbapenemase-production in B. fragilis division II
strains by the MBT STAR-Carba assay
In this assay, we included all those isolates, independent of the
meropenem or imipenem MICs measured (Table 2), which gave
positive PCR results for the cfiA gene (altogether 70 isolates). As
negative control, 33 B. fragilis isolates with negative PCR results for
the cfiA gene were randomly selected from the B. fragilis strains
belonging to Division I. The STAR-Carba assay detected the imipe-
nem hydrolysis in all 70 cfiA-positive B. fragilis strains, and in none
of the 33 cfiA-negative strains involved in this part of the study
independent of the MICs of meropenem. The 11 B. fragilis strains
with high meropenem MIC values (16mg/L) showed a full imi-
penem hydrolysis after 30min, while the 59 strains with lower
meropenemMIC value (<16mg/L, ranged between 0.125 and 8mg/
L) achieved it after 60min (Fig. 1, Table 3).
The logRQ score values at 30min showed a correlation with the
meropenem and imipenem MIC values (r¼ 0.57 and r¼ 0.77,
respectively), regardless the absolute value of the logRQ score.
The comparison between logRQ values at 30min and at 60min
(DlogRQ60min30min) showed a minimal increase or a decrease of
imipenem hydrolysis (average 0.14) among the 11 strains withTable 2
Distribution of imipenem and meropenem MICs of selected B. fragilis strains
belonging to Division II and I originating from two centres.
Strain isolated in (No) Imipenem MIC (mg/L) Meropenem MIC (mg/L)
MIC range MIC50 MIC90 MIC range MIC50 MIC90
B. fragilis Division II
Bologna (29) 0.125-32 4 32 1-32 4 32
Dortmund (41) 0.062e32 1 32 0.125-32 2 32
B. fragilis Division I
Bologna (30) e e e 0.015e2 0.125 0.5
Dortmund (43) e e e 0.015e1 0.062 0.25
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the strains with lower carbapenemMICs (averageþ 0.58) (Table 3).
Among the strains with high level of cfiA expression, only a
minimum increase, or more often a decrease was observed be-
tween the logRQ values at 30min and 60min, indicating that the
full hydrolysis of imipenem was achieved already after 30min.
Conversely, the strains with low level of cfiA expression showed a
significant increase of logRQ between 30min and 60min, sug-
gesting that they required more time to hydrolyze completely the
imipenem. No significant increase between the logRQ values at
30min and 60min was observed among cfiA-negative strains,
proving, beyond the absence of any bacterial hydrolytic activity, a
very good stability of imipenem molecules in the assay (Fig. 1,
Table 3).
3.4. Comparison of the results obtained with three different
carbapenemase detection method
The Carba NP test detected carbapenemase activity in 6 of 29
(20.7%) Division II B. fragilis strains. It gave indeterminate result for
17 (58.6%) strains, andwas negative for 6 isolates most of themwith
meropenemMIC 2mg/L. Disk-diffusion synergy test detected the
B. fragilis carbapenemase in 23 of 29 (79.3%) cases with all the
isolates which had a meropenemMIC 4mg/L with one exception,
strain BF95 (Table 4). Six strains (identical to the Carba NP nega-
tives) gave no interpretable result by synergy test. The strains
detected by both these methods corresponded to those character-
ized by higher meropenem MIC values (8mg/L) (Table 4). The
capability of Carba NP and disk-diffusion synergy test to detect
carbapenemase activity in B. fragilis strains belonging to Division II
was dependent on the meropenem MICs, thus strains with lower
MIC values were not detected, while STAR-Carba assay detected
carbapenemase-activity in all strains, regardless their MICs.
4. Discussion
During this study, the largest number ever of B. fragilis clinical
isolates was tested by MALDI-TOF MS for their status to belong to
Division I/II. Typing was performed using the spectra recorded for
routine identification. We confirmed previous data, underlining
that MALDI-TOF MS-based subtyping immediately performed
during species identification offers the possibility to give pre-
liminary information to clinicians about the presence of carba-
penemase production in B. fragilis [31,32,39]. Previous studies
found that the prevalence of cfiA containing B. fragilis strains,
belonging to Division II, is about 2e7% in the B. fragilis population
obtained from clinical specimens [32,40e43], with only one study
reporting amuch higher prevalence (38% in Turkey) [37]. Regarding
prevalence among blood cultures, a recent study from Denmark
shows reduced susceptibility to carbapenems in 10.2% of isolates
from blood cultures [36]. In this study, interestingly we found
higher percentage of Division II isolates among the strains tested in
Bologna (10.1%) compared to those, which were tested in Dort-
mund (7.6%). An even bigger difference was found for strains iso-
lated from positive blood cultures in the two cities (15.2% in
Bologna and 6% in Dortmund, respectively). This may be due to the
number and composition of the specimens received in the two
different laboratories, but differences in usage of carbapenems in
clinical practice may also contribute.
As viable isolates were only available from 2014 onwards, a
subset of 70 isolates from both study sites, categorized by MALDI-
TOF MS analysis to belong to Division II, was confirmed by PCR.
Further 73 isolates classified as Division I by MALDI-TOF MS were
randomly selected from both test sites for PCR analysis (Table 1).
Similar to earlier studies [31,32], PCR confirmed the presence of thewholeMALDI-basedworkflow from identification to confirmation of
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Fig. 1. STAR-Carba imipenem hydrolysis assay for investigation of the expression level of cfiA. For each sample, spectra of imipenem were recorded after 30 and after 60min of
incubation with the bacterial strain tested.
Two logRQ thresholds are set for interpretation of STAR-Carba assay, visualized by the green line (logRQ¼ 0.2, corresponding to the 20% of imipenem hydrolysis), and the red line
(logRQ¼ 0.4, corresponding to the 40% of hydrolysis). Samples with logRQ 0.2 are negative (not hydrolyzing), samples with logRQ 0.4 are positive (hydrolyzing). LogRQ between
0.2 and 0.4 indicate an ambiguous degree of hydrolysis, that requires to repeat the test.
1a. Negative control: the sample was not hydrolyzing imipenem (logRQ< 0.2) both after 30 and 60min.
1b. cfiA-carrying strain with low expression level: the sample was not hydrolyzing after 30min, but hydrolyzing (logRQ >0.4) after 60min, with a great difference of logRQ between
the two measurements.
1c. cfiA-carrying strainwith high expression level: the sample was hydrolyzing already after 30min of incubation, with no differences of logRQ between the twomeasurements. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Table 3
Comparison of the difference of logRQ values at 30min and 60min in case of cfiA-positive B. fragilis strains (with high and low expression levels) and cfiA-negative strains.
B. fragilis strains Average (range)
LogRQ30min LogRQ60min DlogRQ60min30min
cfiA-positive - high expressiona (n¼ 11) 1.28 (1.05/ 1.44) 1.14 (0.97/1.47) 0.14 (0.44/ þ0.04)
cfiA-positive - low expressionb (n¼ 59) 0.43 (0.69/ 1.38) 1.11 (0.48/ 1.78) þ0.58 (0.03/ 1.57)
cfiA-negative (n¼ 33) 0.44 (0.74/ 0.04) 0.41 (0.74/ 0.11) þ0.03 (0.33/ þ0.65)
a Meropenem MIC 16mg/L.
b Meropenem MIC <16mg/L.
M. Cordovana et al. / Anaerobe xxx (2018) 1e8 5cfiA gene in all B. fragilis strains typed by MALDI-TOF MS to belong
to Division II. No positive PCR result was found among the isolates
categorized to belong to Division I (Table 1).
We also performed susceptibility testing for these PCR
confirmed strains, and found for Division II (cfiA positive) isolates
meropenem MICs between 0.125 and 32mg/L, while imipenem
MICs were between 0.062 and 32mg/L (Table 2). Comparing the
two agents, in most cases the MIC values for meropenemwere 1e4
dilution steps higher than the MIC values for imipenem. This also
has been described in the literature [21] and is also in concordancePlease cite this article in press as:M. Cordovana, et al., Bacteroides fragilis: A
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mination of carbapenem resistance in B. fragilis [43].
Previous surveillance studies have found that highly resistant
strains among clinical isolates of B. fragilis are rare (reports of
0.2e0.3% in Europe and USA [44] and ca. 1% in Japan [42]). In our
subset of B. fragilis isolates, 11 of 70 Division II strains proved to be
highly resistant, with meropenem and imipenem MICs 16mg/L,
corresponding to a prevalence of 1.0% regarding Dortmund, but
slightly higher (1.7%) among all B. fragilis strains isolated in Bologna,
suggesting, again, a different epidemiological/clinical context in thewholeMALDI-basedworkflow from identification to confirmation of
ps://doi.org/10.1016/j.anaerobe.2018.04.004
Table 4
Carbapenem MIC values and results of carbapenemase detection by phenotypical methods and by STAR-Carba. The capability of Carba NP and disk-diffusion synergy test to
detect carbapenemase activity in Division II strains resulted depending on the carbapenems MICs, thus strains with lower MIC values were not detected, while STAR-Carba
assay detected carbapenemase-activity in all strains, regardless their MICs.
Isolates (n¼ 29) MIC (mg/L) Detection of carbapenemase activity by
Meropenem MIC Imipenem MIC Carba NP Test Disk-diffusion synergytest STAR-Carba test
BF-02 >32 >32 POSITIVE POSITIVE POSITIVE HIGH EXPRESSION
BF-13 >32 >32 POSITIVE POSITIVE POSITIVE HIGH EXPRESSION
BF-22 >32 >32 POSITIVE POSITIVE POSITIVE HIGH EXPRESSION
BF-188 >32 >32 POSITIVE POSITIVE POSITIVE HIGH EXPRESSION
BF-04 16 4 POSITIVE POSITIVE POSITIVE low expression
BF-14 8 4 indeterminate POSITIVE POSITIVE low expression
BF-35 8 8 POSITIVE POSITIVE POSITIVE low expression
BF-44 8 4 indeterminate POSITIVE POSITIVE low expression
BF-132 8 0.50 indeterminate POSITIVE POSITIVE low expression
BF-27 4 0.12 indeterminate POSITIVE POSITIVE low expression
BF-63 4 0.12 indeterminate POSITIVE POSITIVE lowexpression
BF-95 4 0.12 negative not interpretable POSITIVE lowexpression
BF-158 4 4 indeterminate POSITIVE POSITIVE low expression
BF-169 4 0.12 indeterminate POSITIVE POSITIVE low expression
BF-178 4 0.12 indeterminate POSITIVE POSITIVE low expression
BF-194 4 4 indeterminate POSITIVE POSITIVE low expression
BF-199 4 4 indeterminate POSITIVE POSITIVE low expression
BF-231 4 4 indeterminate POSITIVE POSITIVE low expression
BF-236 4 0.12 indeterminate POSITIVE POSITIVE low expression
BF-237 4 0.25 indeterminate POSITIVE POSITIVE low expression
BF-279 4 4 indeterminate POSITIVE POSITIVE low expression
BF-313 4 0.25 indeterminate POSITIVE POSITIVE low expression
BF-322 4 2 indeterminate POSITIVE POSITIVE low expression
BF-323 4 0.50 indeterminate POSITIVE POSITIVE low expression
BF-60 2 0.12 negative not interpretable POSITIVE low expression
BF-240 2 4 negative not interpretable POSITIVE low expression
BF-275 2 0.12 negative not interpretable POSITIVE low expression
BF-277 2 0.12 negative not interpretable POSITIVE low expression
BF-205 1 0.50 negative not interpretable POSITIVE low expression
M. Cordovana et al. / Anaerobe xxx (2018) 1e86two datasets. The further investigation for IS elements showed that
only 7 of our 11 highly resistant Division II strains harboured such
promoters upstream the cfiA resistance gene. This has been
described earlier [14,19,35] and underlines that high carbapenem
resistance may also be due to other, yet unknown, cellular factors
increasing the expression of cfiA.
Confirmation test using imipenem hydrolysis and MS mea-
surements by the MBT STAR-Carba assay verified the carbapen-
emase activity in all cfiA-positive strains, with considerable
differences between the cfiA positive isolates with high or lowMICs
for carbapenems. This finding confirms that the cfiA-encoded
enzyme is the dominating carbapenemase in B. fragilis, even if the
gene is not fully expressed. These results are in concordance with
the earlier results of ertapenem hydrolysis assay carried out with
B. fragilis strains belonging to Division II with the cfiA gene pub-
lished by Johansson et al. [33,34], but the method we investigated
here is faster, thanks to the usage of imipenem instead of ertape-
nem. Moreover, the investigated STAR-Carba assay is available as a
ready-to-use kit that allows the prompt confirmation of the
carbapenemase-production in B. fragilis strains immediately after
their classification as belonging to Division II by MALDI-TOF MS
subtyping. This may be of great importance for clinical isolates
involved in life-threatening infections. Further, the rate of imipe-
nem hydrolysis assay enabled a separation of the strains into fast-
hydrolyzers (full hydrolysis of imipenem achieved after 30min)
and slow hydrolyzers (full hydrolysis of imipenem achieved after
60min) as two distinct groups. With regard to the level of resis-
tance, these two groups corresponded to the strains with highMICs
(11 isolates), and with medium to low MICs (59 isolates), respec-
tively. Hence, the possibility to characterize the Division II isolates
in terms of cfiA-expression level byMALDI-TOF MS applications has
been demonstrated for the first time in this study. The cfiAPlease cite this article in press as: M. Cordovana, et al., Bacteroides fragilis: A
carbapenemase production for routine laboratories, Anaerobe (2018), httexpression levels proved to be strongly related with the MIC
interpretative categories (strains with high level of expression fell
in the “resistant” category, while strains with low level of expres-
sion fell in the “intermediate” or “susceptible” category, according
to EUCAST breakpoints). Hence, the use of this novel Biotyper
application could directly affect the antibiotic treatment. In fact,
according with the EUCAST definition of “intermediate”, and for
similarity with the EUCAST guidelines for other kind of
carbapenemase-producing bacteria, carbapenem agents can still be
administered for strains that result intermediate or susceptible
(corresponding, in this study, to the ones which exhibit cfiA low
expression level), but should be avoided for strains exhibiting high
cfiA expression level (corresponding, in this study, only to the
resistant ones).
We also compared the performance of the MS-based workflow
for detection of carbapenemase activity with theworkflowwhich is
applied to detect carbapenemase-production in Enterobacteriaceae
in Bologna, adapted for anaerobes. The MALDI-based workflow
showed to be by far superior to the potential application of the
methods currently available in this laboratory. Compared to con-
ventional methods, the MALDI-TOF MS approach detected 7/29
cfiA-positive strains which were not found by disk diffusion syn-
ergy test, and 24/29 that were negative using Carba NP. Although
strains with high and medium meropenem MICs were detected by
synergy test after 24e48 h, all the lowMIC strains (2mg/l) would
not have been detected. This might be of particular importance,
because activation of cfiA expression under selective pressure
during antibiotic treatment may happen [20,38].
The novel full MALDI-TOF MS-based workflow to identify and
type B. fragilis and even to detect the level of carbapenemase ac-
tivity of the isolates was found to be more precise compared to the
methods currently available for routine practice. Furthermore, thewholeMALDI-basedworkflow from identification to confirmation of
ps://doi.org/10.1016/j.anaerobe.2018.04.004
M. Cordovana et al. / Anaerobe xxx (2018) 1e8 7new approach was much faster for carbapenemase detection in
B. fragilis. The whole approach takes about 2 h of time. Moreover,
frequently subculturing is not necessary, since a few colonies are
enough to perform both MALDI typing and imipenem hydrolysis
assay. Further studies are needed to confirm the applicability of this
concept of subtyping also to other bacteria and resistance mecha-
nisms, any time that a resistance-specific peaks in the mass spectra
are found.
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